Founded in 2020, Immunito AI operates in Health Tech industry. Initially focusing on leveraging AI to streamline the antibody discovery process, the company has evolved to enhance the efficiency and e...
Funding stage:
Series A
Last funding:
24/11/2025
Total funding:
$7.10 Mn+
Revenue:
Investors
Employee count:
25
Last 90d
25
Last 90d
Web traffic:
522
522
Last 30d
Last 30d
Glassdoor Rating:
Immunito AI: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders29
Latest Filing Date19 Nov 2025- Funding Events20
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Immunito AI
As of 20 November 2025, Immunito AI's equity is held by 28 shareholders, with the top three being Trisha Chatterjee, Aridni Shah, and Pi Ventures Fund II.
Trisha Chatterjee holds the largest stake in Immunito AI at 17.7% as of 20 November 2025.
As of 20 November 2025, founders collectively hold 35.3% equity in Immunito AI.
As of 20 November 2025, investors collectively hold 50.2% equity in Immunito AI.
Immunito AI's ESOP pool stands at 14.0% of total equity as of 20 November 2025.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links